

Kayentis

Dedicated to eCOA and patient engagement

Kayentis closes 3.6 M€ growth financing round

kayentis · Thursday, October 13th, 2016

Innovation Capital and Extens finance 3.6 M€ round to accelerate the international growth of Kayentis.



Kayentis, a global provider of electronic Clinical Outcome Assessment (eCOA) solutions for patient and data collection in clinical trials, announced today the completion of a 3.6 M€ growth financing round.

The round was led by Innovation Capital whose SISA fund - dedicated to private equity investments in innovative digital health companies in Europe - contributed the bulk of the financing. The historical investors, Extens, Lénapart and KCE, reinvested alongside Innovation Capital.

Kayentis has specialized in eCOA solutions for patient and data collection in clinical trials since 2009, developing a full range of services and extending its solutions portfolio to support pharmaceutical companies, biotechnology companies and CROs.

With the experience of more than 120 clinical trials in 75 countries (6,000 sites and 50,000 patients) and in a broad range of therapeutic areas, Kayentis adds value to data quality and clinical trial efficiency with innovative and intuitive solutions, and has two development priorities: Patient Engagement and Risk-based Monitoring.

The funds raised will enable Kayentis to further accelerate its growth internationally through increased investments in Sales, Marketing and R&D, and position the company as a leading global provider of eCOA solutions.

“This round of financing validates our development model and our significant growth

prospects. It also provides Kayentis with the means to continue improving our technological platform and value-added services to better serve our clients worldwide. I am particularly pleased to welcome Innovation Capital as a new investor or and business partner to accompany us in this new and exciting growth phase for Kayentis. I also thank the existing investors for their continuous support”, said Guillaume Juge, CEO of Kayentis.

Franck Noiret, General Partner of Innovation Capital, declared: “We are delighted to partner with Kayentis and its experienced management team. This is the 7th investment of our SISA fund dedicated to the financing of innovative digital health companies in Europe. Kayentis has had an impressive track record in the last few years and we are confident it will continue to grow fast. We strongly believe that Kayentis has what it takes to become a leading global provider of eCOA solutions in the next few years.”

“Thanks to its portfolio of solutions and quality of service, Kayentis has become a partner of choice in the industry of clinical trials. The strong development of the company confirms our decision to back them two years ago. We have reinvested in this round with the aim to make Kayentis a major eCOA player in the world”, added Arnaud Houette, Managing Director of Extens.

About Kayentis

Kayentis is a global provider of electronic Clinical Outcome Assessment (eCOA) solutions for patient data collection in clinical trials. Created in 2003, Kayentis has specialized in eCOA solutions since 2009, developing a full range of services and extending its solutions portfolio to support pharmaceutical companies, biotechnology companies and CROs. Today, with experience of more than 120 clinical trials in 75 countries (6,000 sites and 50,000 patients) and in a broad range of therapeutic areas, Kayentis adds value to data quality and clinical trial efficiency with innovative and intuitive solutions, and has two development priorities: Patient Engagement and Risk-based Monitoring.

Contact: *Guillaume JUGE, President and CEO - Kayentis - gjuge@kayentis.com - +33 1 69 18 25 40*

Twitter [@MyKayentis](https://twitter.com/MyKayentis) - www.kayentis.com

About Innovation Capital

Founded in 1996, Innovation Capital is an international venture capital firm based in Paris with a local presence in the Silicon Valley.

With over €450 million under management, Innovation Capital’s current focus is on venture and growth investments in the digital health space in Europe. The portfolio of the SISA fund currently includes the following companies: Voluntis, Fittingbox, Zesty, Wandercraft, Biomodex, H4D and Kayentis.

Innovation Capital aims to create value by providing talented entrepreneurs with the resources, experience and network necessary to turn innovative technologies and services into great businesses. www.innovationcapital.fr

Contact: Franck NOIRET, General Partner - franck.noiret@innovationcapital.fr - +33 6 72 81 35 17

About Extens

Founded in 2014, Extens Développement e-Santé is a sectoral investment vehicle dedicated to the digital transformation of healthcare. Positioned as a growth fund, Extens invests from 1 to 7 M€ in profitable or nearly profitable companies generating 1 to 20 M€ in revenue with strong growth potential. Its investment targets include: software for hospitals, applications software for healthcare professionals, monitoring solutions for patient at home and health data applications. www.extens.eu

Contact: Arnaud HOUETTE, Managing Director - arnaud.houette@extens.eu - +33 6 70 88 25 98

// Download the press release //

This entry was posted on Thursday, October 13th, 2016 at 11:23 am and is filed under [Kayentis news](#)

You can follow any responses to this entry through the [Comments \(RSS\)](#) feed. Both comments and pings are currently closed.